Company Filing History:
Years Active: 2009
Introduction
Françoise De Laveleye-Defais is a distinguished inventor based in Brussels, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the development of VLA-4 inhibitors. With his innovative approach, De Laveleye-Defais is making strides in addressing various inflammatory diseases.
Latest Patents
De Laveleye-Defais holds a patent for the invention of 2,6-quinolinyl and 2,6-naphthyl derivatives. The patent outlines processes for preparing these compounds, as well as their pharmaceutical applications. Specifically, these derivatives serve as VLA-4 inhibitors, which are crucial in treating a range of inflammatory diseases such as asthma, allergic rhinitis, and rheumatoid arthritis. The patented formulation is characterized by the molecular structure defined in formula (I), where X can be either nitrogen (N) or a carbon-hydrogen bond (CH).
Career Highlights
Currently, Françoise De Laveleye-Defais works at UCB Pharma S.A., a leading global biopharmaceutical company. His role involves leveraging his expertise to advance therapeutic solutions that address unmet medical needs. His work not only highlights his innovative capabilities but also reflects the commitment of UCB Pharma to improving patient outcomes through research-driven approaches.
Collaborations
Throughout his career, De Laveleye-Defais has collaborated with talented coworkers, including Marie-Agnès Lassoie and Laurent Knerr. These partnerships have enhanced the research environment at UCB Pharma, fostering the sharing of ideas and innovation. Together, they work to develop new pharmaceutical compositions and therapies that have the potential to change the landscape of treatment for inflammatory diseases.
Conclusion
Françoise De Laveleye-Defais stands out as an accomplished inventor in the pharmaceutical industry, particularly with his patented discoveries aimed at VLA-4 inhibition. His commitment to scientific research and collaboration at UCB Pharma underscores the importance of innovation in developing effective treatments for complex inflammatory conditions. As the field continues to evolve, De Laveleye-Defais’ contributions will undoubtedly play a vital role in enhancing therapeutic options and improving patient care.